• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尿毒症患者铝过载的防治:长期结果

Prevention and treatment of aluminum overload in uremic patients: long-term results.

作者信息

Canavese C, Thea A, Pacitti A, Salomone M, Mangiarotti G, Segoloni G, Stratta P, Gurioli L, Constantini S, Giordini R

机构信息

Department of Nephrology, S. Giovanni-Molinette Hospital, University of Torino, Italy.

出版信息

Clin Nephrol. 1989 Apr;31(4):169-74.

PMID:2714022
Abstract

The authors evaluate the efficacy of a protocol of prevention and treatment of aluminum (Al) overload in RDT patients during a 7-year period (from 1981, 164 patients, to 1987, 161 patients). Al in dialysate solutions was always less than 25 micrograms/l. Baseline Al levels greater than 100 micrograms/l were found in 22% of patients in 1981 but in none in 1987, while the percentage of values less than 60 micrograms/l increased from 55 to 91%. DFO tests were positive in 54% and 7% of cases in 1981 and 1987, respectively. A clinical diagnosis of Al intoxication was performed in 6 patients in 1981, and no further cases were diagnosed later. DFO treatment (50 mg/kg once a week) was employed preventively in 31 patients owing to positive DFO-tests, and in the 6 Al-intoxicated patients therapeutically. In the former patients none developed clinical intoxication. In the latter group clinical improvement was only temporary in the three parathyroidectomized patients. Al hydroxide [Al(OH)3] as a phosphate binder was tapered off in 1981 and substituted by Al-free chelants. In 1987, 66% of patients were given CaCO3 or Mg (OH)2 alone or in association, while 34% still needed Al(OH)3, although at low dosages (less than 2 g/day). The conclusion is that such a protocol is able to prevent and to treat cases of Al intoxication, albeit only partially.

摘要

作者评估了一项在7年期间(从1981年的164例患者到1987年的161例患者)对接受规律透析治疗(RDT)患者预防和治疗铝(Al)过载方案的疗效。透析液中的铝含量始终低于25微克/升。1981年,22%的患者基线铝水平高于100微克/升,但1987年无一例出现这种情况,而低于60微克/升的比例从55%增加到了91%。去铁胺(DFO)试验在1981年和1987年的阳性率分别为54%和7%。1981年有6例患者被临床诊断为铝中毒,之后未再诊断出其他病例。由于DFO试验呈阳性,31例患者接受了预防性DFO治疗(每周一次,50毫克/千克),6例铝中毒患者接受了治疗性DFO治疗。在前者中,无人发生临床中毒。在后者中,3例甲状旁腺切除患者的临床改善只是暂时的。1981年逐渐停用氢氧化铝[Al(OH)3]作为磷结合剂,并代之以无铝螯合剂。1987年,66%的患者单独或联合使用碳酸钙(CaCO3)或氢氧化镁[Mg(OH)2],而34%的患者仍需要Al(OH)3,尽管剂量较低(每天少于2克)。结论是,这样的方案能够预防和治疗铝中毒病例,尽管只是部分有效。

相似文献

1
Prevention and treatment of aluminum overload in uremic patients: long-term results.尿毒症患者铝过载的防治:长期结果
Clin Nephrol. 1989 Apr;31(4):169-74.
2
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.1α(OH)D3 一α-羟基胆钙化醇——一种活性维生素 D 类似物。关于慢性透析的尿毒症患者继发性甲状旁腺功能亢进症预防和治疗的临床研究。
Dan Med Bull. 2008 Nov;55(4):186-210.
3
Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity.去铁胺治疗铝中毒透析患者的临床经验。
Q J Med. 1990 Mar;74(275):257-76.
4
[Aluminum poisoning in dialysis patients--diagnosis and therapy].[透析患者的铝中毒——诊断与治疗]
Schweiz Rundsch Med Prax. 1994 Jun 14;83(24):738-56.
5
Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload.使用低剂量去铁胺试验来诊断和区分患有铝相关性骨病、铝中毒风险增加或铝过载的患者。
Nephrol Dial Transplant. 1995 Oct;10(10):1874-84.
6
Low serum aluminum values in dialysis patients with increased bone aluminum levels.骨铝水平升高的透析患者血清铝值较低。
Clin Nephrol. 1998 Aug;50(2):69-76.
7
Comparison of low-dose deferoxamine versus standard-dose deferoxamine for treatment of aluminium overload among haemodialysis patients.低剂量去铁胺与标准剂量去铁胺治疗血液透析患者铝过载的比较。
Nephrol Dial Transplant. 2010 May;25(5):1604-8. doi: 10.1093/ndt/gfp649. Epub 2009 Nov 30.
8
Aluminum concentrations in serum, dialysate, urine and bone among patients undergoing continuous ambulatory peritoneal dialysis (CAPD).持续非卧床腹膜透析(CAPD)患者血清、透析液、尿液和骨骼中的铝浓度。
Clin Nephrol. 1989 Sep;32(3):133-8.
9
Clinical and histological results of long-term management of aluminium overloading in uraemic patients with desferrioxamine.去铁胺对尿毒症患者铝过载进行长期治疗的临床及组织学结果
J Trace Elem Electrolytes Health Dis. 1989 Mar;3(1):17-23.
10
Calcium alginate, an aluminum-free phosphate binder, in patients on CAPD.在持续性非卧床腹膜透析患者中使用的藻酸钙,一种无铝的磷结合剂。
Clin Nephrol. 1989 Aug;32(2):96-100.

引用本文的文献

1
Aluminum transfer during dialysis: a systematic review.透析过程中的铝转运:一项系统评价。
Int Urol Nephrol. 2014 Jul;46(7):1361-5. doi: 10.1007/s11255-014-0752-8. Epub 2014 Jun 18.
2
Efficacy of low-dose desferrioxamine for the estimation of aluminium overload in haemodialysis patients.低剂量去铁胺对血液透析患者铝过载评估的疗效
Pharm World Sci. 1996 Oct;18(5):187-91. doi: 10.1007/BF00820731.
3
Calcium carbonate as a phosphate binder in dialysis patients: evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia.
Klin Wochenschr. 1991 Jan 22;69(2):59-67. doi: 10.1007/BF01666818.